Biologicals in the management of rheumatodermatologic conditions and beyond

Biologicals are synthesized from living cells by biotechnology methods and typically include monoclonal antibodies and fusion proteins targeted against pathogenic cytokines, B or T cells, or its receptors. A biosimilar is a cheaper, manufactured product which is almost the same as biological. Approp...

Full description

Bibliographic Details
Published in:Clinical Dermatology Review
Main Authors: C B Mithun, B Harikrishnan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Subjects:
autoimmune
biological
connective tissue disease
rheumatodermatological
Online Access:http://www.cdriadvlkn.org/article.asp?issn=2542-551X;year=2019;volume=3;issue=1;spage=41;epage=46;aulast=Mithun
Description
Summary:Biologicals are synthesized from living cells by biotechnology methods and typically include monoclonal antibodies and fusion proteins targeted against pathogenic cytokines, B or T cells, or its receptors. A biosimilar is a cheaper, manufactured product which is almost the same as biological. Appropriate patient selection is the key consideration before starting biologicals. Screening for tuberculosis is a must, except in case of rituximab. Tumor-necrosis-factor alpha inhibitors, interleukin (IL)-17A antagonists, anti-CD6 monoclonal antibodies (mAbs), and anti-IL-6 mAbs are discussed here for various indications.
ISSN:2542-551X
2542-5528

Similar Items